HieraBio
CompanySouth Korea
HieraBio develops one asset, in phase 1 (HB1011 in ischemic cardiomyopathy). Mostly cell therapy acting on stem cell maintenance; based in South Korea.
- 1
- Asset
- Furthest stage
- Phase 1
- 1
- Trial
- 1
- Signal
Pipeline
1Allogeneic myocardium-derived mesenchymal stem cells to repair and regenerate damaged heart muscle
Phase 1, Cell therapy, Stem cell maintenance, ischemic cardiomyopathy
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms1
- Trials1
- Signals1
- Similar companies6